Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

Study:

A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up

Rationale:

n/a

Purpose:

To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Diabetes, Type I Drug: Technosphere Insulin
Drug: Active comparator		 Phase 3

Verified by Mannkind Corporation October, 2009

Sponsored by: Mannkind Corporation
Information provided by: Mannkind Corporation
ClinicalTrials.gov identifier: NCT00308308

Study Type: Interventional

Study Design: Allocation: Randomized, Control: Dose Comparison, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.